Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733680 · ClinicalTrials.gov registry record · Early Phase 1
Amiloride Hydrochloride as an Effective Treatment for ADHD
A Early Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01733680 is a Early Phase 1 study that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 3 participants.
The verdict
NCT01733680, a Early Phase 1 study, was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inhibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.
Interventions
- BEHAVIORAL Behavioral
- DRUG amiloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733680
The ClinicalTrials.gov registry entry for NCT01733680 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Behavioral is the first listed.
NCT01733680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733680 about?
NCT01733680 is a clinical study titled "Amiloride Hydrochloride as an Effective Treatment for ADHD". The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inhibit, initiate, self-correc...
What is the current status of trial NCT01733680?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2012-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01733680?
The interventions under investigation include: Behavioral (BEHAVIORAL), amiloride (DRUG).
Who is sponsoring clinical trial NCT01733680?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.